NASDAQ: CELZCreative Medical Technology Holdings Inc Stock
$1.94-0.03 (-1.52%)
Updated Apr 21, 2025
CELZ Price
$1.94
Fair Value Price
$4.00
Market Cap
$3.39M
52 Week Low
$1.69
52 Week High
$6.90
P/E
-0.52x
P/B
0.53x
P/S
310.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$11.00k
Earnings
-$5.49M
Gross Margin
60%
Operating Margin
-49,940.74%
Profit Margin
-49,940.7%
Debt to Equity
0.05
Operating Cash Flow
-$5M
Beta
0.37
Next Earnings
May 8, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CELZ Overview
Creative Medical Technology Holdings, Inc. is a biotechnology company that focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. Offerings include CaverStem to treat erectile dysfunction, FemCelz for the treatment of loss of genital sensitivity and dryness, StemSpine to treat chronic lower back pain, ImmCelz for the treatment of stroke patients, and OvaStem for treatment of female infertility. Creative Medical Technology was founded in 1998 and is based in Phoenix, AZ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CELZ's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CELZ
Ranked#299 of 462
Ranked#299 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important CELZ news, forecast changes, insider trades & much more!
CELZ News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CELZ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CELZ ($1.94) is undervalued by 51.46% relative to our estimate of its Fair Value price of $4.00 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CELZ ($1.94) is significantly undervalued by 51.46% relative to our estimate of its Fair Value price of $4.00 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CELZ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CELZ due diligence checks available for Premium users.
Valuation
CELZ fair value
Fair Value of CELZ stock based on Discounted Cash Flow (DCF)
Price
$1.94
Fair Value
$4.00
Undervalued by
51.46%
CELZ ($1.94) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CELZ ($1.94) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CELZ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CELZ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.52x
Industry
-184.27x
Market
27.14x
CELZ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.53x
Industry
4.04x
CELZ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CELZ's financial health
Profit margin
Revenue
$3.0k
Net Income
-$1.9M
Profit Margin
-61,802.5%
CELZ's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CELZ's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.7M
Liabilities
$327.6k
Debt to equity
0.05
CELZ's short-term assets ($6.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CELZ's short-term assets ($6.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CELZ's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CELZ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.9M
Investing
$0.0
Financing
$1.6M
CELZ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CELZ vs Biotech Stocks
Creative Medical Technology Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.